Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImClone, Repligen, Massachusetts Institute of Technology biomanufacturing news

The parties settled a 2004 suit against IMCL that alleged the manufacture of Erbitux cetuximab infringes MIT's U.S. Patent No. 4,663,281, which is exclusively licensed to RGEN

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE